NuvOx Pharma is a clinical stage biotech company developing an innovative platform of oxygen therapeutics to treat life-threatening diseases where hypoxia plays a role.
Location: United States, Arizona, Tucson
Employees: 11-50
Founded date: 2008
Investors 6
| Date | Name | Website |
| - | Arizona Te... | arizonatec... |
| 03.01.2024 | Band of An... | bandangels... |
| - | VisionTech... | visiontech... |
| 05.03.2023 | New World ... | newworldan... |
| - | K2X | k2x.capita... |
| - | Arizona Te... | azti.membe... |
Mentions in press and media 13
| Date | Title | Description |
| 13.02.2024 | Meet February Pitch Presenter Aegle Therapeutics’ Shelley Hartman: Healing with EVs | Last year was a very good year for VisionTech. Applying strict criteria, we completed 18 deals worth $2.88 million. We’re continuing our thesis this year, looking hard at leadership, the unmet needs being met, milestones achieved, and deal ... |
| 30.05.2023 | VisionTech Angels Invest $196,500 in NuvOx Therapeutics | Tucson, Arizona-based clinical stage biotechnology company developing a first-in-class therapeutic that uses oxygen to amplify treatment of life-threatening diseases. |
| 20.02.2023 | Meet Our February Pitch Presenter: Dr. Evan Unger of NuvOx Pharma, Using Oxygen to Amplify Treatments | I was introduced to Dr. Evan Unger by Mike Eckert of the NOLA Angel Network in New Orleans. Their group is syndicating an investment opportunity in NuvOx Pharma, a clinical stage pharmaceutical company developing a drug that significantly i... |
| 02.06.2017 | NuvOx Pharma: Breathing new life into an old contrasting agent | It was a good idea, according to judges of the Pitch Perfect competition at the MedCity INVEST conference in May. Unger’s pitch took first place in the biopharma track. In a follow-up interview, NuvOx Business Development Assoc. John McGoni... |
| 19.05.2017 | From medical imaging to dental robotics, MedCity’s Best of INVEST Pitch Perfect contest 2017 | To accommodate numerous entries in the health IT track, the group was split between one segment with companies that had raised more than $2 million, which was sponsored by OSF Healthcare, and those that had raised less than $2 million, a co... |
| 18.05.2017 | Three “hits” on biopharma market trends at mcINVEST | Creative drug pricing and reimbursement In early April, Amgen made a bold and possibly trend-setting promise concerning its new LDL cholesterol-lowering drug Repatha. If patients taking the PCSK9 inhibitor (for at least six months) experien... |
| 09.02.2016 | Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M | “We believe in having multiple antigens, not just one,” Brooks said. “We’re involved in bispecific and trispecific antigens.” So far, Aurora been operating largely on some $15 million in grant funding, from the NIH and various charities. It... |
| - | Three “hits” on biopharma market trends at mcINVEST | Day one of MedCity INVEST, an annual healthcare investment conference held in Chicago, highlighted different facets of today’s biopharma industry — from startups to VCs to Big Pharma partnerships. It began with a panel discussion on hot inv... |
| - | From medical imaging to dental robotics, MedCity’s Best of INVEST Pitch Perfect contest 2017 | The expression “May you live in interesting times” can sound as much like a curse as a blessing, it seems. On the one hand, the turn of events in Washington over the past few months give cause for concern, especially with the uncertainty ar... |
| - | Bucking the Trend: VisionTech Angels Invest $2.88 Million in 18 Deals, Nearly a Half a Million More than in 2022 | INDIANAPOLIS, Indiana (January 23, 2024) – – In a report issued January 4 by Crunchbase, global investing in startups stalled in 2023, declining by 38%, the lowest level in five years. Lackluster investing left startups scrambling for capit... |
Show more